SwePub
Sök i LIBRIS databas

  Utökad sökning

(WFRF:(Wojdyla Daniel M.))
 

Sökning: (WFRF:(Wojdyla Daniel M.)) > (2015-2019) > Clinical consequenc...

Clinical consequences of bleeding among individuals with a recent acute coronary syndrome : Insights from the APPRAISE-2 trial

Sharma, Abhinav (författare)
Duke Univ, Duke Clin Res Inst, Sch Med, Durham, NC USA;McGill Univ, Div Cardiol, Hlth Ctr, Montreal, PQ, Canada;Stanford Univ, Div Cardiol, Stanford Sch Med, Stanford, CA 94305 USA
Hagström, Emil (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Institutionen för medicinska vetenskaper
Wojdyla, Daniel M. (författare)
Duke Univ, Duke Clin Res Inst, Sch Med, Durham, NC USA
visa fler...
Neely, Megan L. (författare)
Duke Univ, Duke Clin Res Inst, Sch Med, Durham, NC USA
Harrington, Robert A. (författare)
Stanford Univ, Div Cardiol, Stanford Sch Med, Stanford, CA 94305 USA
Wallentin, Lars, 1943- (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Institutionen för medicinska vetenskaper
Alexander, John H. (författare)
Duke Univ, Duke Clin Res Inst, Sch Med, Durham, NC USA
Goodman, Shaun G. (författare)
Univ Toronto, St Michaels Hosp, Terrence Donnelly Heart Ctr, Toronto, ON, Canada
Lopes, Renato D. (författare)
Duke Univ, Duke Clin Res Inst, Sch Med, Durham, NC USA
visa färre...
 (creator_code:org_t)
MOSBY-ELSEVIER, 2019
2019
Engelska.
Ingår i: American Heart Journal. - : MOSBY-ELSEVIER. - 0002-8703 .- 1097-6744. ; 215, s. 106-113
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background Patients with a recent acute coronary syndrome (ACS) receiving oral antiplatelets and anticoagulants are at risk for bleeding and subsequent adverse non-bleeding-related events. Methods In this post hoc analysis, we evaluated 7,392 high-risk patients (median follow-up 241 days) with a recent ACS randomized to apixaban or placebo in APPRAISE-2. Clinical events during a 30-day period after Thrombolysis in Myocardial Infarction (TIMI) major/minor bleeding were analyzed using unadjusted and adjusted Cox proportional-hazards models. Results In total, 153 (2.1%) patients experienced TIMI major/minor bleeding during follow-up. Bleeding risk for patients on triple therapy (apixaban, thienopyridine, and aspirin) was increased compared with those on dual therapy (apixaban plus aspirin: hazard ratio [HR] 2.02, 95% CI 1.08-3.79; thienopyridine plus aspirin: HR 1.99, 95% CI 1.41-2.83). Those receiving apixaban/aspirin had similar bleeding risk compared with those receiving thienopyridine/aspirin (HR 1.01, 95% CI 0.53-1.95). Patients who experienced TIMI major/minor bleeding had an increased risk of 30-day all-cause mortality (HR 24.7, 95% CI 15.34-39.66) and ischemic events (HR 6.7, 95% CI 3.14-14.14). Conclusions In a contemporary cohort of high-risk patients after ACS, bleeding was associated with a significantly increased risk of subsequent ischemic events and mortality regardless of antithrombotic or anticoagulant strategy. Patients receiving apixaban plus aspirin had a similar bleeding risk compared with those receiving thienopyridine plus aspirin. Interventions to improve outcomes in patients after ACS should include strategies to optimize the reduction in ischemic events while minimizing the risk of bleeding.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy